NIKKEI 225
37,960.61 +332.13 (+0.88%) HANG SENG
17,626.75 +342.21 (+1.98%) CRUDE OIL
83.87 +0.30 (+0.36%) GOLD FUTURES
2,347.40 +4.90 (+0.21%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,497.63 +160.01 (+0.31%)
Genfit S.A. (0QT6.L)
| Previous close | 3.9505 |
| Open | 3.8360 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.8940 - 3.9300 |
| 52-week range | 3.1150 - 4.9000 |
| Volume | |
| Avg. volume | 22,360 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023). Third edition of the Extra-Financial Performance report Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to
- GlobeNewswire
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 1
- Globe Newswire
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the filing of its 2023 Universal Registration Document with the Autorité des marchés financiers (AMF ; filing n° D.24-0246) and its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities
